Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC- NCIC trial. Lancet Oncol 10:459–466
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolamide for glioblastoma. N Engl J Med 2005; 10, 352: 987-396. Wen PY, and Khesari S Malignant gliomas in Adults. N Engl J Med 2008; 359:492-507.
Bauman G, Lote KL, Larson D, et al: Pretreatment factors predict overall survival for patients with low-grade glioma : a recursive partitioning analysis. Int J Radiation Oncology Biol Phys 1999; 45 (4): 923-929.
Karim ABMF, Afra D, Cornu P et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European organization for research and treatment of cancer study 22845 with the medical research council study BRO4. an interim analysis. Int. J. Radiat. Oncol. Biol. Phys. 52, 316-324 ( 2002).
Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson S et al:Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low- grade gliomas. J Neurosurg 2000; 86: 747-754.
Massimino M, Spreafico F, Cefalo G, Riccardi R, Tesoro-Tess J, Gandola L et al: High response rate to Cisplatin/Etoposide in childhood low-grade glioma. J Clin Oncol 2002; 20: 4209-4216.
Prados MD, Edwards MSB, Rabbitt J, et al: Treatment of pediatric low-grade gliomas with nitrosurea-based multiagent chemotherapy regimem. J Neuroncol 1997; 32: 235-241
Tada K, Shiraishi S, Kamiryo T et al: Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patients age and survival. J Neurosurg 2001; 95: 651-659.
Cairncross JG, Ueki K, Zlatescu M, et al: Specific predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90:1473-1479.
Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, Polivka M, Criniere E, Marie Y, Mokhtari K, Carpentier AF, Laigle F, Simon JM, Cornu P, Broet P, Sanson M, Delattre JY: Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.
Eyre HJ, Crwley JJ, Townsend JJ et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J. Neurosurg. 78: 909-914, 1993.
Buckner JC et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 21: 251-255, 2003
Quinn JA, Reardon DA, Friedman AH, et al:Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma. J Clin Oncol 2003; 21: 646-651.
Pace A, Vidiri A, Galiè E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Annals of Oncology. 2003 ;14 (12):1722-6.
Brada M, Viviers L, Abson C, et al: Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Annals of Oncology 2003; 14 (12): 1715-1721.
van den Bent MJ, Wefel JS, Schiff D,et al Response assessment in neuro- oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas The Lancet Oncology - 6 April 2011
Carson KA, Grossman SA, Fisher JD et al. Prognostic factor for survival in adult with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 25: 2601-6, 2007
Stummer W, van den Bent MJ, Westphal M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir (Wien) 2011; 153:1211–1218.
Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008; 62:753–766
Westphal M, Hilt DC, Bortey E. et al. A phase 3 trial of local chemotherapy with biodegradable carmustine(BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma Neuro-Oncology 5: 79-88, 2003.
Carapella CM, Telera S, Oppido PA. Surgery of malignant gliomas: advances and perspectives. Curr Opin Oncol. 23(6):624-9, 2011.
Brada M, Stenning S, Gabe R et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol. 2010 Oct 20;28(30):4601-8
Vredenburgh JJ, Desjardin A, Herndon JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25: 4722-9, 2007
Friedman et al. A phase II randomized, non comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS) in recurrent, treatment refractory glioblastoma (GBM),, J Clin Oncol 2009
Cairncross G, Macdonald D, Ludwin S. et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994 Oct;12(10):2013-21
Triebels VH, Taphoorn MJB, Brandes AA et al. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology 2004;63: 904–906.
van den Bent MJ, Chinot O, Boogerd W et al. Second-line chemotherapy with Temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 2003;14:599–602.
Mohan DS, Suh JH, Phan JL, et al. Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Int J Radiat Oncol Biol Phys 42:981–987, 1998.
Keime-Guiber F, Chinot O, Taillandier L et al (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527– 1535
Chinot OL, Barrie M, Frauger E et al (2004) Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 100:2208– 2214.
Glantz M, Chamberlain M, Liu Q et al (2003) Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97:2262–2266. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003.
Minniti G, De Sanctis V, Muni R, Filippone F, Bozzao A, Valeriani M et al (2008) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 88(1):97–103